Skip to content
Screener

Travere Therapeutics, Inc. TVTX Short-Term Investments

Short-Term Investments at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.75B+14.9%
Jade Biosciences logo
Jade BiosciencesJBIO
$256.21M+701%
Vera Therapeutics logo
Vera TherapeuticsVERA
$482.41M-9.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$816.54M+83.1%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$76.25M-50.8%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$197.6M+14.9%

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001438533-26-000042
Line itemRemaining Contractual Maturity(in years)Amortized CostUnrealized GainsUnrealized LossesAggregate Estimated Fair Value
Commercial paperLess than 1$29,913$(20)$29,893
Corporate debt securitiesLess than 195,8442(153)95,693
Municipal bondsLess than 15,000(1)4,999
Total maturity less than 1 year130,7572(174)130,585
Corporate debt securities1 to 245,8927(151)45,748
Securities of government-sponsored entities1 to 210,000(19)9,981
Total maturity 1 to 2 years55,8927(170)55,729
Total available-for-sale marketable debt securities$186,649$9$(344)$186,314

Item 1. Financial Statements

FAQ

What is Travere Therapeutics, Inc.'s short-term investments?
Travere Therapeutics, Inc. (TVTX) reported short-term investments of $130.59M in Q1 2026.
What is the long-term trend for Travere Therapeutics, Inc.'s short-term investments?
Over 4 years (2020 to 2025), Travere Therapeutics, Inc.'s short-term investments has grown at a -14.5% compound annual growth rate (CAGR), from $271.8M to $145.38M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.

Ask your AI about Travere Therapeutics, Inc.'s short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude